RO7204239

Phase 1Small molecule

Roche

RO7204239 is one of 45 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Type 2 Diabetes MellitusActive, not recruiting

Type 2 Diabetes MellitusPhase 1

Active, not recruiting

Competition

Competitive Landscape

150 competitors in Type 2 Diabetes Mellitus

#DrugCompanyPhaseTrials

DWP16001

Daewoong Pharmaceutical Co. LTD.

Phase 3

5 2

Maridebart Cafraglutide

Amgen

Phase 3

3 3

Retatrutide

Eli Lilly

Phase 3

1 4

Elecoglipron

AstraZeneca

Phase 3

5 5

Imeglimin

PPoxel SA

Phase 3

1 6

Dorzagliatin

HHua Medicine Limited

Adenocard

1 8

NOVOLIN R

Novo Nordisk

Preclinical

1 9

Dostinex

Golytely

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Facioscapulohumeral Muscular Dystrophy

NCT05548556

PreclinicalActive, not recruiting

Spinal Muscular Atrophy (SMA)

NCT05115110

Q1 2027

Phase 1Active, not recruiting

Type 2 Diabetes Mellitus

NCT07137585

Phase 2Active, not recruiting

Obesity

NCT06965413

Clinical

Trials by Indication[1]

Facioscapulohumeral Muscular Dystrophy1 trial

A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Pharmacodynamics, Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7204239 in Participants With Facioscapulohumeral Muscular Dystrophy

Active, not recruiting· Roche logo

Roche·Phase 2·NCT05548556·51 enrolled

Spinal Muscular Atrophy (SMA)1 trial

A Two-Part, Seamless, Multi-Center, Randomized, Placebo-Controlled, Double-Blind Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Patients With Spinal Muscular Atrophy

Active, not recruiting· Roche logo

Roche·Preclinical·NCT05115110·97 enrolled

Obesity1 trial

A Randomized, Double-blind, Placebo-controlled Phase 2 Trial to Assess Efficacy, Safety, and Tolerability of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity

Active, not recruiting· Roche logo

Roche·Phase 2·NCT06965413·285 enrolled

Type 2 Diabetes Mellitus1 trial

Effects of RO7204239 on Insulin Sensitivity, Muscle Composition and Function in Participants Living With Type 2 Diabetes Mellitus and Overweight or Obesity: A Double-blind, Randomized, Placebo-controlled Study

Active, not recruiting· Roche logo

Roche·Phase 1·NCT07137585·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for RO7204239. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RO7204239 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RO7204239. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Roche

RO7204239

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Trials by Indication[1]

Facioscapulohumeral Muscular Dystrophy1 trial

Spinal Muscular Atrophy (SMA)1 trial

Obesity1 trial

Type 2 Diabetes Mellitus1 trial

References

Drug Info

Quick Facts

Related News